References

Biliary tract cancer

10.1016/s0140-6736(21)00153-7 · 2021 · External reference

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

10.1586/egh.10.45 · 2010 · External reference

Immune checkpoint therapy—current perspectives and future directions

10.1016/j.cell.2023.03.006 · 2023 · External reference

A phase 3, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1

10.1007/s12072-020-10030-4 · 2020 · External reference

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer

10.1056/evidoa2200015 · 2022 · External reference

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

10.1016/s0140-6736(23)00727-4 · 2023 · External reference

KEYNOTE-966 trial in progress: pembrolizumab added to gemcitabine and cisplatin for advanced biliary tract cancer

10.1002/hep.31579 · 2020 · External reference

KEYNOTE-966: a randomized, double-blind, placebo-controlled, phase 3 study of pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract carcinoma

10.1158/1538-7445.am2020-ct283 · 2020 · External reference

Unresolved reference

2020 · External reference

Activity and safety of gemcitabine + durvalumab combination in cisplatin-ineligible unresectable locally advanced or metastatic biliary tract cancer

10.1177/03008916241277279 · 2024 · External reference

Unresolved reference

2019 · External reference

Effect of GEMOX regimen combined with immunotherapy on efficacy and tumor markers in patients with advanced cholangiocarcinoma

10.3969/j.issn.1002-7386.2023.12.022 · 2023 · External reference

Efficacy of pembrolizumab combined with chemotherapy in patients with advanced intrahepatic cholangiocarcinoma and its effect on tumor markers

10.3969/j.issn.1674-4985.2023.16.001 · 2023 · External reference

Effect of PD-1 inhibitor combined with chemotherapy versus chemotherapy alone as first-line treatment on efficacy and progression-free survival in patients with advanced cholangiocarcinoma

2023 · External reference

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: a large real-life worldwide population

10.1016/j.ejca.2024.114199 · 2024 · External reference

Real-world outcomes of chemotherapy plus immune checkpoint inhibitors versus chemotherapy alone in advanced, unresectable, and recurrent intrahepatic cholangiocarcinoma

10.3389/fimmu.2024.1390887 · 2024 · External reference

Efficacy and safety of camrelizumab combined with chemotherapy in the treatment of advanced biliary malignancy and associations between peripheral blood lymphocyte subsets and clinical outcomes

10.1007/s12094-024-03707-x · 2025 · External reference

First-line chemotherapy or in combination with programmed cell death protein-1 antibody in patients with metastatic or recurrent biliary tract cancer

10.1111/jgh.15668 · 2021 · External reference

Integrating immunotherapy into chemotherapy: real-world efficacy of GEMOX plus tislelizumab in advanced gallbladder cancer

10.1080/1120009x.2025.2568807 · 2025 · External reference

Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration

10.1007/s00262-024-03796-1 · 2024 · External reference

Durvalumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in biliary tract cancer: a real-world retrospective, multicenter study

10.1007/s11523-024-01060-1 · 2024 · External reference

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

10.1016/s2468-1253(24)00095-5 · 2024 · External reference

PD-8 outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study

10.1016/j.annonc.2022.04.086 · 2022 · External reference

Durvalumab (DUR) effectiveness in advanced biliary tract cancer (aBTC) patients based on real-world data evidence

10.1200/jco.2025.43.4_suppl.598 · 2025 · External reference

KEYNOTE-966 phase III clinical study: pembrolizumab plus gemcitabine plus cisplatin versus gemcitabine plus cisplatin alone for advanced biliary tract malignancies

10.3969/j.issn.1001-5256.2023.11.033 · 2023 · External reference

47P first-line pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC) in the China subpopulation from the phase III KEYNOTE-966 study

10.1016/j.annonc.2024.08.056 · 2024 · External reference

Toripalimab in advanced biliary tract cancer

10.1016/j.xinn.2022.100255 · 2022 · External reference

Efficacy and conversion outcome of chemotherapy combined with PD-1 inhibitor for patients with unresectable or recurrent gallbladder carcinoma: a real-world exploratory study

10.1186/s12957-025-03703-7 · 2025 · External reference

94P first-line chemotherapy plus immunotherapy versus chemotherapy alone for advanced gallbladder carcinoma

10.1016/j.iotech.2023.100566 · 2023 · External reference

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study

10.1016/s2468-1253(22)00043-7 · 2022 · External reference

Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: a multicenter, phase 2 trial

10.1002/ijc.33751 · 2021 · External reference

346P revealing biomarkers of response to chemo-immunotherapy in biliary tract cancer

10.1016/j.annonc.2025.05.361 · 2025 · External reference

IL-21 and IL-33 may be effective biomarkers to predict the efficacy of PD-1 monoclonal antibody for advanced cholangiocarcinoma

10.1089/cbr.2024.0149 · 2025 · External reference

Impact of hepatitis B virus infection on the efficacy and safety of pembrolizumab plus chemotherapy for advanced biliary tract cancer in the KEYNOTE-966 study

10.1158/2767-9764.crc-25-0633 · 2026 · External reference